A Multicenter Pilot Study of Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Targeted Immunotherapy in Children, Adolescents and Young Adults With Poor Risk CD30+ Hodgkin Lymphoma (HL)
Phase of Trial: Phase I/II
Latest Information Update: 03 Apr 2018
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 28 Mar 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 28 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 25 Jun 2014 New trial record